Stanford University
Showing 2,681-2,690 of 4,398 Results
-
Ramesh Nair
Director of Bioinformatics, SCGPM, Genetics
Current Role at StanfordDirector, Bioinformatics
Stanford Center for Genomics and Personalized Medicine (SCGPM)
Bioinformatics-as-a-Service (BaaS)
Genetics Bioinformatics Service Center (GBSC)
Diabetes Genomics Analysis Core (DGAC)
Stanford University School of Medicine -
Michitaka Nakano
Basic Life Research Scientist, Medicine - Med/Hematology
BioI am a MD/PhD postdoctoral fellow and medical oncologist with a long-standing interest in translational cancer research. My long-term goal is to be a lab-based physician-scientist and independent academic researcher, translating basic cancer research, and mentoring next-generation scientists. My thesis work in Japan focused on cancer stem cell equilibrium by uniquely applying organoid culture as a method to elucidate cancer stem cell dynamics, which was awarded in Japanese Cancer Association. Along with the development of the field represented by success in T cell checkpoint, my interest gradually shifted to immune oncology while I examined numerous numbers of cancer patients as a medical oncology fellow. My postdoctoral fellowship at Calvin Kuo Lab in Stanford (2019-present) focuses on tumor immune microenvironment. Kuo lab developed a unique 3D air-liquid interface (ALI) organoid system that cultures tumors while preserving their endogenous infiltrating immune cells (T,B ,NK, Myeloid cells). My postdoctoral work will prove the significance of organoids as a translational tool to discover tumor-immune interaction by novel checkpoint inhibitors for immune cells, which can be broadly applicable to basic cancer biology, precision medicine, therapeutics validation and biomarker discovery.
-
Yusuke Nakauchi, MD, PhD
Basic Life Research Scientist, Stem Cell Bio Regenerative Med Institute
BioMy research projects aim to investigate the biology of human leukemia. I believe my research will contribute to clarify the disease pathogenesis of leukemia and help identify the critical cells to target to both prevent the development of de novo leukemia and halt relapse.
